Market Cap 77.03M
Revenue (ttm) 62.04M
Net Income (ttm) -227.46M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -366.63%
Debt to Equity Ratio 0.00
Volume 761,400
Avg Vol 1,010,060
Day's Range N/A - N/A
Shares Out 85.14M
Stochastic %K 38%
Beta 1.75
Analysts Sell
Price Target $2.68

Company Profile

Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneu...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 881 6500
Fax: 650 553 9659
Address:
111 Oyster Point Boulevard, South San Francisco, United States
PaulLaurent
PaulLaurent Nov. 16 at 8:12 PM
🧭 Weekly Swing Recap $IFRX – +25% from the entry zone. Steady push; trims into strength worked. $TNYA – +35% from the entry zone. Clean trend; partials on pushes paid. $GALT – +17% from the entry zone. Approach to first target; protect gains. $STRO – +24% from the entry zone. Higher-lows held; respect VWAP. $AVIR – ~+10% at peak, but catalyst reversal hit Stop-Loss if profits weren’t taken. GPRO – Near breakeven — small profit only, limited follow-through.
1 · Reply
slickstoc
slickstoc Nov. 16 at 1:30 PM
0 · Reply
KY3000
KY3000 Nov. 15 at 8:09 PM
$STRO it’s time for vaxcyte to open an oncology division, they have nothing going on after vax 31 ped/adult. Spin back.
0 · Reply
StockScanners
StockScanners Nov. 15 at 4:27 AM
$STRO reached .99
0 · Reply
Zaksab
Zaksab Nov. 14 at 5:15 PM
$STRO If you can exquisitely construct ADC's with dual targets and dual payloads that either address unmet needs or offer material increments to the extants solution (ie patent extender) then you could have something. Right now it's in reset mode. You'd probably have to believe the legacy cell free synthesis platform offers some sort of distinction in a field that is obviously very crowded. Most gems start unpolished but most unpolished gems end in that state.
0 · Reply
KY3000
KY3000 Nov. 14 at 3:13 PM
$STRO $EXEL needs to step up
0 · Reply
KY3000
KY3000 Nov. 14 at 3:12 PM
$STRO IND & 1st patient dose of Astellas iADC has to trigger a major milestone? Does anyone have clarity on milestone schedule?
1 · Reply
KY3000
KY3000 Nov. 14 at 3:10 PM
$STRO 002 is a dar4, reformulate to dar8, and make the dual payload that they already have data on from 2022, solidified the Astellas deal.
0 · Reply
StockScanners
StockScanners Nov. 14 at 2:49 AM
$STRO keep watch if this holds above .87
0 · Reply
KY3000
KY3000 Nov. 13 at 3:12 PM
$STRO this is worth more than mersana, that upri was a disaster
0 · Reply
Latest News on STRO
Sutro Biopharma to Participate in Upcoming Investor Conferences

May 1, 2025, 4:05 PM EDT - 7 months ago

Sutro Biopharma to Participate in Upcoming Investor Conferences


Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline

Mar 14, 2025, 12:09 PM EDT - 8 months ago

Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline


Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless

Jan 2, 2025, 6:28 PM EST - 11 months ago

Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless


Sutro BioPharma: Good Stewardship Through Early Trials

Sep 14, 2023, 1:21 PM EDT - 2 years ago

Sutro BioPharma: Good Stewardship Through Early Trials


PaulLaurent
PaulLaurent Nov. 16 at 8:12 PM
🧭 Weekly Swing Recap $IFRX – +25% from the entry zone. Steady push; trims into strength worked. $TNYA – +35% from the entry zone. Clean trend; partials on pushes paid. $GALT – +17% from the entry zone. Approach to first target; protect gains. $STRO – +24% from the entry zone. Higher-lows held; respect VWAP. $AVIR – ~+10% at peak, but catalyst reversal hit Stop-Loss if profits weren’t taken. GPRO – Near breakeven — small profit only, limited follow-through.
1 · Reply
slickstoc
slickstoc Nov. 16 at 1:30 PM
0 · Reply
KY3000
KY3000 Nov. 15 at 8:09 PM
$STRO it’s time for vaxcyte to open an oncology division, they have nothing going on after vax 31 ped/adult. Spin back.
0 · Reply
StockScanners
StockScanners Nov. 15 at 4:27 AM
$STRO reached .99
0 · Reply
Zaksab
Zaksab Nov. 14 at 5:15 PM
$STRO If you can exquisitely construct ADC's with dual targets and dual payloads that either address unmet needs or offer material increments to the extants solution (ie patent extender) then you could have something. Right now it's in reset mode. You'd probably have to believe the legacy cell free synthesis platform offers some sort of distinction in a field that is obviously very crowded. Most gems start unpolished but most unpolished gems end in that state.
0 · Reply
KY3000
KY3000 Nov. 14 at 3:13 PM
$STRO $EXEL needs to step up
0 · Reply
KY3000
KY3000 Nov. 14 at 3:12 PM
$STRO IND & 1st patient dose of Astellas iADC has to trigger a major milestone? Does anyone have clarity on milestone schedule?
1 · Reply
KY3000
KY3000 Nov. 14 at 3:10 PM
$STRO 002 is a dar4, reformulate to dar8, and make the dual payload that they already have data on from 2022, solidified the Astellas deal.
0 · Reply
StockScanners
StockScanners Nov. 14 at 2:49 AM
$STRO keep watch if this holds above .87
0 · Reply
KY3000
KY3000 Nov. 13 at 3:12 PM
$STRO this is worth more than mersana, that upri was a disaster
0 · Reply
Send_IT_or_stepaside
Send_IT_or_stepaside Nov. 13 at 3:11 PM
$STRO sell the news these Pennie’s don’t hold
0 · Reply
theBigDollarski
theBigDollarski Nov. 12 at 10:58 PM
$MGNX I'm out...this is going to wind up like $STRO
0 · Reply
sixmilliondollarman
sixmilliondollarman Nov. 12 at 5:36 PM
$STRO started new position at .80. Great R&D day!
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 12 at 4:54 PM
$STRO Share Price: $0.81 Contract Selected: May 15, 2026 $2.5 Calls Buy Zone: $0.15 – $0.19 Target Zone: $0.25 – $0.31 Potential Upside: 56% ROI Time to Expiration: 183 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
betaino
betaino Nov. 12 at 4:03 PM
$STRO https://www.globenewswire.com/news-release/2025/11/12/3186439/0/en/Sutro-Biopharma-Highlights-Next-Generation-ADC-Innovation-at-Virtual-R-D-Day.html
0 · Reply
KY3000
KY3000 Nov. 10 at 8:54 PM
$STRO known catalyst on the 12th, this might hit 50 cent
0 · Reply
KY3000
KY3000 Nov. 10 at 3:59 PM
0 · Reply
betaino
betaino Nov. 9 at 8:20 AM
$STRO https://trial.medpath.com/news/2b8277db19bee50b/sutro-biopharma-receives-fda-clearance-for-stro-004-tissue-factor-adc-advances-dual-payload-platform
0 · Reply
KY3000
KY3000 Nov. 7 at 8:49 PM
$STRO a PR that IND accepted & 1st dose phase1 before year end would of kept this above 1$, but the hid it in a 10Q, they had to a received that info before 10Q?, why are they purposely tanking this stock? I feel like the breaking fu$ING laws by these actions
0 · Reply
KY3000
KY3000 Nov. 7 at 8:28 PM
$STRO how does it take a year to deprioritize lavelta? I want to know why the hemorrhageing in the windown. This has been a 14 month bloodbath, almost running a year under1$, what is csuite doing?
0 · Reply
KY3000
KY3000 Nov. 7 at 8:16 PM
$STRO I’m scared of the price when RD day comes. More chance of hitting 50 cent than 1.00, wat a clusterfuk.
0 · Reply
KY3000
KY3000 Nov. 7 at 8:12 PM
$STRO I can’t believe this is the best that csuite can do. Total failure
0 · Reply